|
WO2018153546A1
|
|
Tetrahydropyran and tetrahydrothiopyran methanone derivatives having multimodal activity against pain
|
|
WO2018153545A1
|
|
Piperidine methanone derivatives having multimodal activity against pain
|
|
WO2018100041A1
|
|
Meta substituted phenylpyrazolo- and phenylpyrrolo- pyridazine derivatives having multimodal activity against pain
|
|
WO2018060097A1
|
|
Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
|
|
TW201808300A
|
|
Use of sigma receptor ligands in cancer
|
|
TW201808937A
|
|
Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
|
|
WO2017178515A1
|
|
Piperidinylalkylamide derivatives having multimodal activity against pain
|
|
EP3339304A1
|
|
Quinoline and isoquinoline derivatives for treating pain and pain related conditions
|
|
EP3339307A1
|
|
Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
|
|
EP3336085A1
|
|
Process and intermediate for the preparation of 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone
|
|
US2018312479A1
|
|
Oxa-azaspiro compounds having activity against pain
|
|
CN108137569A
|
|
Substituted morpholine derivative with anti-pain activity
|
|
EP3344620A1
|
|
1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl) piperazin-1-yl)ethanone salts
|
|
EP3328365A1
|
|
Use of sigma receptor ligands in dyslipidemia
|
|
CN107922384A
|
|
There are the amide derivatives of multi-mode activity to pain
|
|
WO2016173710A1
|
|
Spiro-isoquinoline-3,4'-piperidine compounds having activity against pain
|
|
WO2016096127A1
|
|
Methyl-1h-pyrazole alkylamine compounds having multimodal activity against pain
|
|
US2017362215A1
|
|
1-methylpyrazole-piperazine compounds having multimodal activity against pain
|
|
SG11201704530UA
|
|
Use of sigma receptor ligands in osteoarthritis
|
|
CN107001368A
|
|
The 1,9 diazaspiracyclic hendecane compounds with the anti-pain activity of multiplex mode
|
